Hay varias opciones que pueden ayudarle a cubrir los gastos de su medicamento de Genentech. Responda a estas preguntas sencillas para averiguar cuál puede ser la adecuada para usted.

  • ¿Tiene seguro médico?

  • ¿Tiene seguro médico comercial?

    ¿Qué significa esto?
  • ¿Está recibiendo alguna ayuda económica para poder pagar el medicamento?

    ¿Qué significa esto?
  • ¿Tiene 18 años de edad o más?

Puede que Reúna los Requisitos para que se le Derive a la Tarjeta de Copago de Genentech BioOncology

KADCYLA Access Solutions puede derivarle a la Tarjeta de Copago de Genentech BioOncology. Si reúne los requisitos, puede ayudarle con los costos del bolsillo de su medicamento de Genentech.*


Más Información


* Para poder optar a la Tarjeta de Copago de Genentech BioOncology, el paciente debe disponer de un seguro comercial, no debe tener Medicare, Medicaid ni ningún otro seguro público y debe cumplir otros criterios de elegibilidad. También debe aceptar las reglas establecidas en los términos y condiciones del programa. Visite para ver la lista completa de términos y condiciones.

Puede que Reúna los Requisitos para que se le Derive a una Fundación Independiente de Asistencia al Copago

Si necesita ayuda con el copago de su medicamento de Genentech, podemos derivarle a una fundación independiente de asistencia al copago.*


Más Información


* Las fundaciones independientes de asistencia al copago tienen sus propias normas para la elegibilidad. No podemos garantizarle que una fundación le vaya a ayudar. Solo podemos derivarle para que esta le asista con su estado de salud. No respaldamos ni mostramos preferencia económica por ninguna fundación en particular. Las fundaciones a las que le derivemos no son las únicas que pueden ayudarle.

Puede que Reúna los Requisitos para que se le Derive a la fundación Genentech® Access to Care Foundation, o GATCF

La GATCF puede ayudarle a conseguir su medicamento de Genentech de forma gratuita si cumple los requisitos.*


Más Información


* Si cuenta con un seguro médico, primero debe haber probado otros tipos de asistencia a pacientes para ser apto para recibir medicamentos gratis de Genentech a través de la GATCF. Esto incluye la Tarjeta de Copago de Genentech BioOncology y la ayuda de fundaciones independientes de asistencia al copago. También debe cumplir otros criterios financieros. Si no tiene seguro, debe cumplir unos criterios financieros diferentes.

Important Safety Information & Indication

What it Treats

KADCYLA is approved to treat HER2-positive breast cancer that has spread to other parts of the body (metastatic breast cancer) after prior treatment with trastuzumab (Herceptin) and a taxane. Prior treatment could have been for the initial treatment of breast cancer or for the treatment of cancer that had spread to other parts of the body.

Important Safety Information

What is the most important safety information I should know about KADCYLA?

KADCYLA is not the same medicine as trastuzumab (Herceptin).

Liver Problems

  • KADCYLA may cause severe liver problems that can be life-threatening. Symptoms of liver problems may include vomiting, nausea, eating disorder (anorexia), yellowing of the skin (jaundice), stomach pain, dark urine, or itching

Heart Problems

  • KADCYLA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure). Symptoms may include swelling of the ankles or legs, shortness of breath, cough, rapid weight gain of greater than 5 lb in less than 24 hours, dizziness or loss of consciousness, or irregular heartbeat


  • Receiving KADCYLA during pregnancy can result in the death of an unborn baby and birth defects. Birth control should be used while you receive KADCYLA and for 7 months after your last dose of KADCYLA
  • If you are exposed to KADCYLA during pregnancy or become pregnant within 7 months of your last dose of KADCYLA, contact your healthcare provider right away; you are also encouraged to enroll in the MotHER Pregnancy Registry by calling 1-800-690-6720 or visiting
  • You are also encouraged to report exposure to KADCYLA during pregnancy, or if you become pregnant within 7 months of your last dose to Genentech by calling 1-888-835-2555
  • If you are a mother who is breastfeeding, you should talk with your doctor about either stopping breastfeeding or stopping KADCYLA

Contact your doctor right away if you experience symptoms associated with these side effects.

What are the additional possible serious side effects of KADCYLA?

Lung Problems

  • KADCYLA may cause lung problems, including inflammation of the lung tissue, which can be life- threatening. Signs of lung problems may include trouble breathing, cough, tiredness, and fluid in the lungs

Infusion-Related Reactions

  • Symptoms of an infusion-related reaction may include one or more of the following: the skin getting hot or red (flushing), chills, fever, trouble breathing, low blood pressure, wheezing, tightening of the muscles in the chest around the airways, or a fast heartbeat. Your doctor will monitor you for infusion-related reactions

Serious Bleeding

  • KADCYLA can cause life-threatening bleeding. Taking KADCYLA with other medications used to thin your blood (antiplatelet) or prevent blood clots (anticoagulation) can increase your risk of bleeding. Your doctor should provide additional monitoring if you are taking one of these other drugs while on KADCYLA. Life-threatening bleeding may also happen with KADCYLA, even when blood thinners are not also being taken

Low Platelet Count

  • Low platelet count may happen during treatment with KADCYLA. Platelets help your blood to clot. Signs of low platelets may include easy bruising, bleeding, and prolonged bleeding from cuts. In mild cases there may not be any symptoms

Nerve Damage

  • Symptoms may include numbness and tingling, burning or sharp pain, sensitivity to touch, lack of coordination, muscle weakness, or loss of muscle function

Skin Reactions Around the Infusion Site 

  • KADCYLA may leak from the vein or needle and cause reactions such as redness, tenderness, skin irritation, or pain or swelling at the infusion site. If this happens, it is more likely to happen within 24 hours of the infusion

How will my doctor know if KADCYLA is right for me?

You must have a HER2 test to determine if your cancer is HER2-positive before taking KADCYLA, because benefit has been shown only in patients whose tumors are HER2-positive.

What are the most common side effects of KADCYLA?

The most common side effects seen in people taking KADCYLA are:

  • Tiredness
  • Nausea
  • Pain that affects the bones, muscles, ligaments, and tendons
  • Bleeding
  • Low platelet count
  • Headache
  • Liver problems
  • Constipation
  • Nosebleeds

You are encouraged to report side effects to Genentech and the FDA. You may contact Genentech by calling 1-888-835-2555. You may contact the FDA by visiting or calling 1-800-FDA-1088.

Please see the full Prescribing Information for additional Important Safety Information, including most serious side effects, at